458 related articles for article (PubMed ID: 10334255)
1. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Möttönen T; Hannonen P; Leirisalo-Repo M; Nissilä M; Kautiainen H; Korpela M; Laasonen L; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Ilva K; Yli-Kerttula U; Puolakka K; Järvinen P; Hakola M; Piirainen H; Ahonen J; Pälvimäki I; Forsberg S; Koota K; Friman C
Lancet; 1999 May; 353(9164):1568-73. PubMed ID: 10334255
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.
Rantalaiho V; Puolakka K; Korpela M; Hannonen P; Möttönen T
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S27-31. PubMed ID: 23073350
[TBL] [Abstract][Full Text] [Related]
3. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Leirisalo-Repo M; Kautiainen H; Laasonen L; Korpela M; Kauppi MJ; Kaipiainen-Seppänen O; Luosujärvi R; Luukkainen R; Karjalainen A; Blåfield H; Uutela T; Ilva K; Julkunen HA; Paimela L; Puolakka K; Moilanen E; Hannonen PJ; Möttönen T;
Ann Rheum Dis; 2013 Jun; 72(6):851-7. PubMed ID: 22753402
[TBL] [Abstract][Full Text] [Related]
4. Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.
Levitsky A; Wick MC; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; van Vollenhoven RF; Rantalaiho V
Clin Exp Rheumatol; 2016; 34(6):1065-1071. PubMed ID: 27607411
[TBL] [Abstract][Full Text] [Related]
5. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Hakala M; Järvinen P; Ahonen J; Forsberg S; Leirisalo-Repo M;
Arthritis Rheum; 2005 Jan; 52(1):36-41. PubMed ID: 15641055
[TBL] [Abstract][Full Text] [Related]
6. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Boers M; Verhoeven AC; Markusse HM; van de Laar MA; Westhovens R; van Denderen JC; van Zeben D; Dijkmans BA; Peeters AJ; Jacobs P; van den Brink HR; Schouten HJ; van der Heijde DM; Boonen A; van der Linden S
Lancet; 1997 Aug; 350(9074):309-18. PubMed ID: 9251634
[TBL] [Abstract][Full Text] [Related]
7. Remission as the treatment goal--the FIN-RACo trial.
Sokka T; Mäkinen H; Puolakka K; Möttönen T; Hannonen P
Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-74-6. PubMed ID: 17083766
[TBL] [Abstract][Full Text] [Related]
8. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
Möttönen T; Hannonen P; Korpela M; Nissilä M; Kautiainen H; Ilonen J; Laasonen L; Kaipiainen-Seppänen O; Franzen P; Helve T; Koski J; Gripenberg-Gahmberg M; Myllykangas-Luosujärvi R; Leirisalo-Repo M;
Arthritis Rheum; 2002 Apr; 46(4):894-8. PubMed ID: 11953964
[TBL] [Abstract][Full Text] [Related]
9. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
10. Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis.
Laivoranta-Nyman S; Möttönen T; Hannonen P; Korpela M; Kautiainen H; Leirisalo-Repo M; Julkunen H; Luukkainen R; Hakala M; Vuori K; Laine AP; Toivanen A; Ilonen J;
Clin Exp Rheumatol; 2006; 24(6):636-42. PubMed ID: 17207378
[TBL] [Abstract][Full Text] [Related]
11. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
[TBL] [Abstract][Full Text] [Related]
12. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Heimans L; Wevers-de Boer KV; Visser K; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Speyer I; de Buck MP; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
Ann Rheum Dis; 2014 Jul; 73(7):1356-61. PubMed ID: 23716067
[TBL] [Abstract][Full Text] [Related]
13. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
[TBL] [Abstract][Full Text] [Related]
14. Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.
Karstila KL; Rantalaiho VM; Mustonen JT; Möttönen TT; Hannonen PJ; Leirisalo-Repo M; Kaipiainen-Seppänen OA; Karjalainen AH; Korpela MM;
Clin Exp Rheumatol; 2010; 28(1):73-8. PubMed ID: 20346242
[TBL] [Abstract][Full Text] [Related]
15. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
Rantalaiho V; Korpela M; Laasonen L; Kautiainen H; Järvenpää S; Hannonen P; Leirisalo-Repo M; Blåfield H; Puolakka K; Karjalainen A; Möttönen T;
Arthritis Res Ther; 2010; 12(3):R122. PubMed ID: 20576092
[TBL] [Abstract][Full Text] [Related]
16. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
Korpela M; Laasonen L; Hannonen P; Kautiainen H; Leirisalo-Repo M; Hakala M; Paimela L; Blåfield H; Puolakka K; Möttönen T;
Arthritis Rheum; 2004 Jul; 50(7):2072-81. PubMed ID: 15248204
[TBL] [Abstract][Full Text] [Related]
17. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
Rantalaiho V; Kautiainen H; Korpela M; Hannonen P; Kaipiainen-Seppänen O; Möttönen T; Kauppi M; Karjalainen A; Laiho K; Laasonen L; Hakola M; Peltomaa R; Leirisalo-Repo M;
Ann Rheum Dis; 2014 Nov; 73(11):1954-61. PubMed ID: 23908187
[TBL] [Abstract][Full Text] [Related]
18. Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.
Rantalaiho VM; Kautiainen H; Korpela M; Hannonen PJ; Leirisalo-Repo M; Möttönen T;
Ann Rheum Dis; 2013 May; 72(5):786-8. PubMed ID: 23349132
[No Abstract] [Full Text] [Related]
19. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
[TBL] [Abstract][Full Text] [Related]
20. Therapies for active rheumatoid arthritis after methotrexate failure.
O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
